Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

K. Suzuki, K. Sunami, K. Ohashi, S. Iida, T. Mori, H. Handa, K. Matsue, M. Miyoshi, E. Bleickardt, M. Matsumoto, M. Taniwaki

Research output: Contribution to journalLetter

7 Citations (Scopus)
Original languageEnglish
Article numbere540
JournalBlood cancer journal
Volume7
Issue number3
DOIs
Publication statusPublished - 2017 Mar 10

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Suzuki, K., Sunami, K., Ohashi, K., Iida, S., Mori, T., Handa, H., Matsue, K., Miyoshi, M., Bleickardt, E., Matsumoto, M., & Taniwaki, M. (2017). Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis. Blood cancer journal, 7(3), [e540]. https://doi.org/10.1038/bcj.2017.18